Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | OXTR | P30559 | 1/20 | 0.51 |
| ▸ | GPR183 | P32249 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3253825 | 0.88 | AVPR1A (0.63) | KMT2AHRH4AVPR1AMEN1OXTR | |
| SCHEMBL3255715 | 0.80 | NPC1 (0.61) | KMT2AHRH4NPC1RAB9AAVPR1A | |
| SCHEMBL15963109 | 0.79 | AVPR1A (0.59) | NPC1AVPR1AOXTR | |
| SCHEMBL8193722 | 0.78 | KMT2A (0.59) | KMT2AHRH4AVPR1AMEN1OXTR | |
| SCHEMBL15963063 | 0.78 | AVPR1A (0.57) | AVPR1AOXTR | |
| SCHEMBL3256158 | 0.78 | KMT2A (0.61) | KMT2AHRH4NPC1RAB9AAVPR1A | |
| SCHEMBL2351433 | 0.75 | HRH4 (0.78) | KMT2AHRH4NPC1RAB9AMEN1 | |
| SCHEMBL3254763 | 0.75 | GPR183 (0.59) | KMT2AHRH4AVPR1AMEN1GPR183 | |
| SCHEMBL2212100 | 0.74 | AVPR1A (0.61) | HRH4AVPR1AOXTR | |
| SCHEMBL2735825 | 0.74 | HRH4 (0.72) | KMT2AHRH4NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102207-B1 | SPIRO-PIPERIDINE DERIVATIVES AS VIA RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-06-02 | — | — | EP | claimed |
| US-8202993-B2 | 5-bromo-1'-[(6-bromo-1H-indol-2-yl)carbonyl]spiro[indole-3,4'-piperidin]-2(1H)-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202993-B2 | 5-bromo-1'-[(6-bromo-1H-indol-2-yl)carbonyl]spiro[indole-3,4'-piperidin]-2(1H)-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202993-B2 | 5-bromo-1'-[(6-bromo-1H-indol-2-yl)carbonyl]spiro[indole-3,4'-piperidin]-2(1H)-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| EP-2102207-B1 | SPIRO-PIPERIDINE DERIVATIVES AS VIA RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-06-02 | — | — | EP | disclosed |
| EP-2102207-B1 | SPIRO-PIPERIDINE DERIVATIVES AS VIA RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-06-02 | — | — | EP | disclosed |
| EP-2102207-A1 | SPIRO-PIPERIDINE DERIVATIVES AS VIA RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-09-23 | — | — | EP | disclosed |
| US-20080146568-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080146568-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080146568-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-06-19 | — | — | US | disclosed |
| WO-2008068185-A1 | SPIRO-PIPERIDINE DERIVATIVES AS VIA RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008068185-A1 | SPIRO-PIPERIDINE DERIVATIVES AS VIA RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139553-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139553-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139553-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139554-A1 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-06-12 | — | — | US | disclosed |
| US-20080139554-A1 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-06-12 | — | — | US | disclosed |
| US-20080139554-A1 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139553-A1 | SPIRO-PIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | KMT2A 862/4885HRH4 315/4885NPC1 2144/4885 |
| US-20080139554-A1 | SPIRO-PIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | KMT2A 862/4885HRH4 315/4885NPC1 2144/4885 |
| US-20080146568-A1 | SPIRO-PIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | KMT2A 862/4885HRH4 315/4885NPC1 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.